POTENTIAL DRUG DELIVERY SYSTEMS AND DEVICE COMBINATION FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic Obstructive Pulmonary Disease (COPD) presents with chronic lung inflammation and poorly reversible airflow limitation, necessitating bronchodilators for management. The Global Initiative for COPD recommends combining Long-Acting Beta-Agonists (LABAs) and Long-Acting Antimuscarinic Agents (LAMAs) for most COPD patients. Developing fixed LAMA/lABA combinations is crucial. Adding an Inhaled Corticosteroid (ICS) to this combination may offer additional benefits, including preventing exacerbations. The GOLD report emphasizes diagnosis, prevention, exacerbation management, and addressing comorbidities. It advocates for holistic COPD management, integrating pharmacologic and non-pharmacologic approaches. Novel strategies like mono, dual, and triple therapies are recommended. The review highlights COPD's impact on COVID-19, comorbidities, and relevant patents concerning COPD and bronchodilators. The bronchodilator treatments may improve their efficacy in this critical aspect of COPD. Research shows that dual bronchodilation improves lung function and symptoms more consistently than mono-bronchodilation while potentially lowering the risk of exacerbations and disease deterioration and having a similar safety profile.